Development of anti-inflammatory drug

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K19507
• Research Category: Grant-in-Aid for Challenging Research (Exploratory)
• Allocation Type: Multi-year Fund
• Review Section: Medium-sized Section 54:Internal medicine of the bio-information integration and related fields
• Research Institution: Kyoto University
• Principal Investigator: KIM MINSOO 京都大学, 医学研究科, 准教授 (50466835)
• Project Period (FY): 2021-07-09 – 2024-03-31
• Keywords: 病原細菌 / 免疫

Outline of Final Research Achievements

While existing antibiotics have serious problems such as the emergence and spread of multidrug-resistant bacteria and the destruction of the intestinal microflora, new drugs for infectious diseases have been sought to overcome these problems, but few new drugs have been launched since the 2010s.
In this study, we aimed to develop a method for infectious diseases based on a completely new concept, which is different from the mechanism of action of existing antibiotics and small molecule therapeutics and targets the specific mechanism required to induce virulence in pathogenic bacteria. We conducted a compound screening to develop a compound that inhibits macrophage cell death, which is induced during bacterial infection, and examined whether it could be a novel mechanism as a therapeutic agent for infectious diseases.

Free Research Field

感染生物学

Academic Significance and Societal Importance of the Research Achievements

中分子感染症治療薬は、標的への特異性が低いため副作用が起こりやすく、多剤耐性が生まれやすい既存の低分子の弱点を補う新しいモダリティである。本研究で開発された新しい治療戦略は、特異性が高く、副作用が少ないと考えられるので、本剤の成果は慢性細菌感染症や多剤耐性菌・ウイルスによる感染症などへの展開できる考えらえる。
薬剤耐性菌による感染症は、生命を脅かす危険性があり、アンメット・メディカル・ニーズは極めて高い。本研究で開発される新しい概念の感染症治療薬は、新興・再興感染症に対するグローバルな感染症対策に対して更なる貢献が期待できる。